XML 18 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 4,963 $ 1,491 $ 8,430 $ 8,456
In-process research and development 0 80,538 5,990 80,538
General and administrative 3,341 4,247 14,060 10,451
Transaction costs 0 0 0 5,765
Total operating expenses 8,304 86,276 28,480 105,210
Loss from operations (8,304) (86,276) (28,480) (105,210)
Other income (expense), net:        
Loss on sale of NTN assets 0 0 0 (9,648)
Change in fair value of warrant liabilities 1,024 0 10,493 0
Loss on non-controlling investment (21) 0 (932) 0
Other (expense) income, net (10) 290 (1,166) 265
Total other income (expense), net 993 290 8,395 (9,383)
Loss before income taxes (7,311) (85,986) (20,085) (114,593)
Provision for income taxes (5) 0 (5) 0
Net loss (7,316) (85,986) (20,090) (114,593)
Series A preferred stock dividend 0 0 (8) (8)
Net loss attributable to common stockholders $ (7,316) $ (85,986) $ (20,098) $ (114,601)
Net loss per common share - basic (in dollars per share) $ (2.49) $ (34.03) $ (7.04) $ (56.79)
Net loss per common share - diluted (in dollars per share) $ (2.49) $ (34.03) $ (7.04) $ (56.79)
Weighted average shares outstanding - basic (in shares) 2,941 2,527 2,855 2,018
Weighted average shares outstanding - diluted (in shares) 2,941 2,527 2,855 2,018